These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27934817)

  • 21. Oral and intravenous fosfomycin in complicated urinary tract infections.
    López-Montesinos I; Horcajada JP
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):37-44. PubMed ID: 31131591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of colistin and fosfomycin resistance in carbapenem-resistant Enterobacteriaceae from a tertiary care hospital in Karachi.
    Qamar S; Shaheen N; Shakoor S; Farooqi J; Jabeen K; Hasan R
    Infect Drug Resist; 2017; 10():231-236. PubMed ID: 28814888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential of fosfomycin in treating multidrug-resistant infections in children.
    Williams PC
    J Paediatr Child Health; 2020 Jun; 56(6):864-872. PubMed ID: 32294306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
    Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
    Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of antibiotic-resistant infection in the newborn.
    Gray JW; Patel M
    Arch Dis Child Educ Pract Ed; 2011 Aug; 96(4):122-7. PubMed ID: 21586610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn].
    Zhang JP; Yang XS; Chen J; Peng YZ; Huang YS
    Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.
    Samonis G; Maraki S; Rafailidis PI; Kapaskelis A; Kastoris AC; Falagas ME
    Future Microbiol; 2010 Jun; 5(6):961-70. PubMed ID: 20521939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients.
    Kapoor K; Jajoo M; Dublish S; Dabas V; Gupta S; Manchanda V
    Pediatr Crit Care Med; 2013 Jul; 14(6):e268-72. PubMed ID: 23689704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
    Shorr AF; Pogue JM; Mohr JF
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New antibiotic agents for bloodstream infections.
    Vergidis PI; Falagas ME
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.
    Trinh TD; Smith JR; Rybak MJ
    Pharmacotherapy; 2019 Nov; 39(11):1077-1094. PubMed ID: 31487056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
    Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
    Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colistin: an antibiotic and its role in multiresistant Gram-negative infections.
    Loho T; Dharmayanti A
    Acta Med Indones; 2015 Apr; 47(2):157-68. PubMed ID: 26260559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME; Feola DJ; Rapp RP
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.